The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.